NCT02320812View on ClinicalTrials.gov

Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 19, 2017

Study Completion Date

July 19, 2017

Conditions
Retinitis Pigmentosa (RP)
Interventions
BIOLOGICAL

human retinal progenitor cells

single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)

Trial Locations (2)

90074

Retina-Vitreous Associates Medical Group, Los Angeles

Unknown

The Gavin Herbert Eye Institute, Univ California Irvine, Irvine

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

jCyte, Inc

INDUSTRY

NCT02320812 - Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter